# Formation Bio

> AI-native pharma company in-licensing and accelerating clinical-stage drug development.

## Why it is interesting

Formation Bio pairs tech-enabled trial ops with drug in-licensing; a16z led a $372M Series D with Sequoia and Thrive among returning investors.

## Profile

- **Stage:** growth
- **Status:** private
- **Industries:** healthtech, biotech-life-sciences
- **Coverage:** full
- **Last updated:** 2026-07-24

## Key facts

- Series D (2024): $372M led by a16z (/fund/andreessen-horowitz) with Sequoia (/fund/sequoia) and Thrive Capital (/fund/thrive-capital) participation (PR Newswire)
- Sanofi also participated; company formerly known as TrialSpark (press)

## Investors in our directory

- https://venturecapitaltracker.com/fund/andreessen-horowitz
- https://venturecapitaltracker.com/fund/sequoia
- https://venturecapitaltracker.com/fund/thrive-capital

---
Source: https://venturecapitaltracker.com/startup/formation-bio